Piper Sandler downgraded Health Catalyst (HCAT) to Neutral from Overweight with a price target of $4, down from $8. The company’s bookings disappointed in the first half of 2025 and its cut revenue guidance for the remaining of the year on lower net revenue retention and churn, the analyst tells investors in a research note. The firm says Health Catalyst’s 2025 guide-down removes all organic growth from the outlook while the company sees revenue declining year-over-year in 2026. Piper expects the shares to be range bound given the lack of organic growth.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HCAT:
- Health Catalyst Earnings Call: Growth Amid Challenges
- Health Catalyst Faces Uncertainty Amid Leadership Change and Revenue Guidance Cut
- Health Catalyst price target lowered to $6 from $10 at Wells Fargo
- Health Catalyst’s Strategic Restructuring and Cost Management Justify Buy Rating Despite Revenue Guidance Reduction
- Health Catalyst downgraded to Neutral from Buy at Citi